Effect of an Extended "Kidney Disease: Improving Global Outcomes" (KDIGO) Bundle Versus Standard of Care Therapy on Persistent Acute Kidney Injury in High-risk Patients After Major Surgery
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Acute Kidney Injury (Nontraumatic)
- Sponsor
- University Hospital Muenster
- Enrollment
- 480
- Locations
- 1
- Primary Endpoint
- Occurrence of persistent severe AKI
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
There is no specific therapy for acute kidney injury. It is presumed that supportive measures improve the care and outcome of patients with acute kidney injury.
To investigate whether an implementation of a supportive extended care "bundle" in high-risk patients for persistent acute kidney injury (AKI) can reduce the occurrence of persistent surgical AKI.
In order to investigate whether the extended KDIGO bundle can prevent persistent AKI in patients with high chemokine ligand 14 (CCL14) as well as in patients with low CCL14, patients will be randomized with stratification by the CCL-value.
Detailed Description
All patients will receive standard of care therapy according to the standards of our center. After identifying surgical patients with a moderate or severe (stage 2 or 3) AKI patients will be randomly allocated to the control or intervention group according to the CCL14 results which will be measured as part of the study. According to the literature, patients with a CCL14 \<1.3ng/ml are at low risk of progression and patients with a CCL14≥1.3ng/ml are at high risk of AKI progression. In order to have both patient groups included, we will have two groups (patients at low and at high risk of AKI progression) and these will be randomized to receive either standard of care or an extended KDIGO bundle (in total 4 groups). Control intervention / reference test: Patients in the control groups will be treated according to the standard of care. The only two hemodynamic targets in this group are the mean arterial pressure (mean arterial pressure (MAP)\>65mmHg) and passive leg raising test (PLRT) (increase of cardiac output (CO) \<10%). In the intervention groups, an extended KDIGO guideline bundle will be implemented (Discontinuation of all nephrotoxic agents when possible, optimization of volume status and perfusion pressure, consideration of a functional hemodynamic monitoring, close monitoring of serum creatinine and urine output, avoidance of hyperglycemia, consideration of alternatives to radio contrast agents, non-invasive or invasive diagnostic workup, nephrology consultation)
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult patients (age ≥18 years)
- •Moderate or severe AKI ((defined by the 2012 KDIGO criteria, KDIGO stage 2 and 3), determined by either serum creatinine or urine output) within 72h after a surgical procedure
- •Written informed consent
Exclusion Criteria
- •Dialysis-dependent chronic kidney disease
- •Prior kidney transplant
- •Infections with human immunodeficiency virus or hepatitis
- •Hepatorenal syndrome
- •Pregnancy or breast-feeding
- •Participation in another interventional trial that investigates a drug that affects the kidney function within the last 3 months
- •Persons held in an institution by legal or official order
- •Persons with any kind of dependency on the investigator or employed by the responsible institution or investigator
Outcomes
Primary Outcomes
Occurrence of persistent severe AKI
Time Frame: 72 hours after start of intervention
The primary endpoint is the development of persistent severe (stage 3) AKI lasting for at least 72h defined as ≥3-fold increase in serum creatinine in relation to baseline or serum creatinine ≥4.0mg/dl with an acute increase of 0.5mg/dl or a decrease in urine output \<0.3ml/kg/h for 24 hours or anuria for 12 hours. Persistent AKI is defined as follows: patients with stage 3 AKI at enrollment require a persistence of 72h or more to meet the endpoint. Patients enrolled at stage 2 AKI require a progression to stage 3 within 48 hours and a persistence at stage 3 for 72 consecutive hours to be considered endpoint positive. Additionally, patients with severe AKI who fail to achieve 72h due to death or the initiation of renal replacement therapy are considered endpoint positive as well
Secondary Outcomes
- Duration of vasopressors(during hospital stay (up to 90 days after start of intervention))
- Fluid balance(during intensive care unit stay)
- Duration of renal replacement therapy(up to 28 days)
- Rate of renal replacement therapy(up to 28 days)
- Rate of persistent renal dysfunction(365 days after start of intervention)
- Number of patients with major adverse kidney events (MAKE)(90 days after start of intervention)
- Hospital length of stay(up to 90 days after start of intervention)
- Rate of infection during intensive care unit stay(during intensive care unit stay (up to 28 days after start of intervention))
- Need of renal replacement therapy (RRT)(365 days after start of intervention)
- Rate of mortality(365 days after start of intervention)
- Length of intensive care unit stay(up to 90 days after start of intervention)
- Dose of vasopressors(during intensive care unit stay)
- Sequential organ failure assessment (SOFA) score(daily at days 28 after start of intervention)